Individualized tumor-reactive T cells exhibit a potent anti-tumor response in prostate cancer.

ABSTRACT:

Background

Cellular immunotherapy exhibits promise in treating blood tumors. However, its application for solid tumors is impeded by their heterogeneity and complex microenvironments. The development of individualized multitarget therapy may be the key to overcoming the challenge of tumor heterogeneity.

Methods

To generate tumor-reactive T cells, we modified the conditional reprogramming primary cell culture method by to establish a primary prostate cancer cell culture approach, refer to as eCR (enhanced conditional reprogramming). Then, Tumor tissue-derived primary cells were physically lysed and loaded into dendric cells, which, in turn, were co-cultured with peripheral blood T cells to induced individualized tumor-reactive T cells.

Results

Our improved culture meth

SUBMITTER: He L 

PROVIDER: S-EPMC11904561 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature